Literature DB >> 4352326

Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro.

T Ono, S Kurata, K Wakabayashi, Y Sugawara, M Saito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4352326

Source DB:  PubMed          Journal:  Gan        ISSN： 0016-450X


× No keyword cloud information.
  10 in total

1.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

Authors:  H Wakasugi; K Oshimi; M Miyata; Y Morioka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

4.  Coordinated therapeutic effects of immune modulators and interferon.

Authors:  I Cerutti; C Chany
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

5.  Clinical studies on streptococcal preparation (OK-432) combined with mitomycin-C, 5-FU and cytosine arabinoside in advanced cancer patients.

Authors:  T Hattori; M Nimoto; S Yamagata; T Tohge
Journal:  Jpn J Surg       Date:  1975-09

6.  Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice.

Authors:  S Kai; J Tanaka; K Nomoto; M Torisu
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study.

Authors:  K Sugimachi; Y Maehara; K Akazawa; Y Kondo; Y Kunii; M Kitamura; H Yamaoka; Y Takahashi; T Kito; M Katou
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.

Authors:  Y Maehara; S Inutsuka; H Takeuchi; H Baba; H Kusumoto; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer.

Authors:  A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF).

Authors:  M Katano; T Mizoguchi; H Yamamoto; M Nakamura; T Matsuo; T Hisatugu; T Kisu; K Yamaoka; O Tokunaga
Journal:  Jpn J Surg       Date:  1990-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.